A carregar...
Potential options for managing LOX+ ER− breast cancer patients
Overexpression of lysyl oxidase (LOX) is often observed in estrogen receptor negative (ER–) breast cancer patients with bone metastasis. In the present bioinformatics study, we observed that LOX is a prognostic factor for poor progression free survival in patients with ER– breast cancer. LOX overexp...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5078060/ https://ncbi.nlm.nih.gov/pubmed/27147578 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.9073 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|